Sign In
Buy ACST
$3.37
+0 (+0%)
At Close: Jan 24, 2025
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha
Acasti Announces $7.5 Million Private Placement Equity Financing
08:00am, Tuesday, 26'th Sep 2023
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine th
Acasti to Participate in the H.C. Wainwright Global Investment Conference
08:00am, Wednesday, 06'th Sep 2023
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine th
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
07:00am, Friday, 11'th Aug 2023
PRINCETON, N.J, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
04:05pm, Wednesday, 09'th Aug 2023
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of nimodipine
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients
09:00am, Monday, 10'th Jul 2023
STRIVE-ON is a pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH LAVAL, QB, July 10, 2023 /PRNe
Acasti Pharma Announces 1-for-6 Reverse Stock Split
08:00am, Friday, 07'th Jul 2023
LAVAL, QB, July 7, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addr
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
11:18am, Tuesday, 28'th Feb 2023
Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript
03:53pm, Tuesday, 14'th Feb 2023
Acasti Pharma Inc. (NASDAQ:ACST ) Q3 2023 Earnings Conference Call February 14, 2023 1:00 PM ET Company Representatives Jan D'Alvise - President, Chief Executive Officer Brian Ford - Chief Financial O
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
04:15pm, Tuesday, 24'th Jan 2023
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
09:00am, Friday, 13'th Jan 2023
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
01:16pm, Wednesday, 28'th Dec 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript
11:23pm, Monday, 14'th Nov 2022
Acasti Pharma Inc. (NASDAQ:ACST ) Q2 2023 Earnings Conference Call November 14, 2022 1:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Jan D'Alvise - President & CEO Brian Ford - CFO P
Acasti Pharma to Present at Q4 Investor Summit
04:15pm, Wednesday, 09'th Nov 2022
LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical
